Exchange: NASDAQ·Updated 07:50 PM EDT
News
all
press releases
Amgen Q2 Earnings Preview: Will the Beat Streak Continue?
Amgen heads into Q2 earnings with a history of beats as investors watch key drug sales trends and seek updates on its MariTide obesity candidate.
Zacks
More News
AMGEN ANNOUNCES 2026 THIRD QUARTER DIVIDEND
AMGEN ANNOUNCES 2026 THIRD QUARTER DIVIDEND AMGEN ANNOUNCES 2026 THIRD QUARTER DIVIDEND PR Newswire THOUSAND OAKS, Calif., July 30, 2026 THOUSAND OAKS, Calif., July 30, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.52 per share dividend for the...
PR Newswire
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Zacks
VKTX Stock Lags GLP-1 Peers In July — But Viking CEO Says Its Obesity Drug Could Offer What Rivals Can’t
Viking expects oral VK2735 Phase 3 studies to begin in Q4 and believes the pill could become the first oral dual GLP-1 agonist to reach the market.
Stocktwits
Amgen (AMGN) Stock Moves -1.44%: What You Should Know
In the closing of the recent trading day, Amgen (AMGN) stood at $387.42, denoting a -1.44% move from the preceding trading day.
Zacks
Earnings Preview: EyePoint (EYPT) Q2 Earnings Expected to Decline
EyePoint (EYPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
Watch Out, Eli Lilly and Novo Nordisk: Amgen's Monthly Weight Loss Drug Has 6 Phase 3 Trials Running -- and It's Coming for Your Patients
Key PointsAmgen wants a slice of the weight loss drug market...
Nasdaq News: Markets
AMGEN ANNOUNCES WEBCAST OF 2026 SECOND QUARTER FINANCIAL RESULTS
AMGEN ANNOUNCES WEBCAST OF 2026 SECOND QUARTER FINANCIAL RESULTS AMGEN ANNOUNCES WEBCAST OF 2026 SECOND QUARTER FINANCIAL RESULTS PR Newswire THOUSAND OAKS, Calif., July 28, 2026 THOUSAND OAKS, Calif., July 28, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its second...
PR Newswire
Earnings Preview: Amgen (AMGN) Q2 Earnings Expected to Decline
Amgen (AMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
AZN Q2 Earnings and Sales Beat, Key Drugs Offset Generic Pressure
AstraZeneca tops Q2 earnings and revenue estimates as strong demand for oncology and rare disease drugs helps offset growing generic competition across key products.
Zacks
<
1
2
>

Advertisement|Remove ads.